Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.
Colorectal Cancer provides a concise, readable overview of current and future management options in a fast-moving field, ideal for the busy clinician or healthcare professional.
Each issue will provide high-quality Reviews of current and emerging topics, cutting-edge Editorials discussing contentious issues and independent Drug Evaluations assessing individual medicines and their role in current treatment practices. In addition, forward-looking Perspectives and Interviews will give leading experts the opportunity to present criticism or address controversy. The journal will also provide a disease-specific forum for Case Studies and Original Research Articles reporting new clinical findings.
Coverage includes:
Risk factors and prevention
Hereditary nonpolyposis colorectal cancer and other hereditary conditions causing colorectal cancer
Biomarkers for screening
Colonoscopy and sigmoidoscopy for screening and diagnosis
Surgery
Radiation therapy
Optimum chemotherapy regimes to maximize efficacy and minimize side effects
Monoclonal antibodies
Multimodality treatment
Prospects for new treatments, such as vaccines
Treatment of metastases
Follow-up care for colorectal cancer survivors
The journal welcomes unsolicited article proposals.
Journal metrics
Citation metrics
2.7 (2023) Impact Factor
2.4 (2023) 5 year IF
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Heinz-Josef Lenz, University of Southern California, USA
Editorial Board
Dirk Arnold, University Cancer Center, Hamburg Elizabetg Barry, Geisel School of Medicine at Dartmouth,USA Anne Marie Bouvier, University of Bourgogne, France Gina Brown, Royal Marsden Hospital, UK Alfredo Carrato, Ramon y Cajal University Hospital, Madrid, Spain Antoni Castells, MD, PhD. University of Barcelona, Spain James Church, Cleveland Clinic, USA Fortunato Ciardiello, Second University of Naples, Italy Cathy Eng, MD Anderson Cancer Center, USA Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA (USA) Alfredo Falcone, University of Pisa, Italy George Fisher Jr, Stanford University, USA Volker Heinemann,University of Munich, Germany Sandy Heriot, Peter MacCallum Cancer Centre, Australia John Marshall, MD, Georgetown University, USA Graeme Poston, Aintree University Hospitals, UK Anthony Shields, Wayne State University, USA Giuseppe Tonini, University Campus Bio-Medico John Zalcberg, Peter MacCallum Cancer Center, Australia
Open access
Colorectal Cancer is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![F1000Research. The Oncology Gateway. Accepting multiple article types. Submit now.]({"type":"image" , "src" : "/sda/112413/JournalAd-F1000-Oncology.jpg"})